How long does remission last on ruxolitinib + azacitidine?
The duration of remission on ruxolitinib with azacitidine depends on the disease being treated and how “remission” is defined in the study (overall response, complete remission, duration of response, etc.). The provided information here does not include any specific clinical trial results or outcome definitions for remission duration with the ruxolitinib–azacitidine combination, so an exact time window (weeks vs months, or how durable responses are) can’t be stated accurately from the available details.
Does “remission duration” mean a CR duration or response duration?
In trials of ruxolitinib-containing regimens, reported endpoints may include:
- Complete remission (CR) and time to CR (a “what happened” endpoint),
- Duration of response (how long the response lasted after it occurred),
- Transfusion independence or symptom response (in myelofibrosis-like settings).
Those measures can produce different “remission duration” numbers even within the same study population. Without the specific study data and endpoint wording, the best answer is that remission duration is not a single fixed number for this regimen.
What if you mean myelofibrosis versus another ruxolitinib use?
Ruxolitinib is most commonly associated with myelofibrosis, but it can be used in other myeloid contexts. Remission durability differs substantially by indication and patient risk profile. If you can share the indication (e.g., myelofibrosis) and the trial/regimen schedule (dose and whether it is strictly “ruxolitinib + azacitidine”), I can translate the study’s reported endpoint into a clear remission-duration estimate.
What data I’d need to answer with numbers
To give a precise duration-of-remission statement, you’d need at least one of the following from the paper or trial report:
- The indication and disease risk group,
- The trial name/phase or NCT number,
- The specific remission endpoint (CR duration vs duration of response),
- The reported median duration (and whether it’s by response category).
DrugPatentWatch.com source?
DrugPatentWatch.com is useful for patents and exclusivity, not for remission-duration clinical outcomes. For remission duration, the key source would be the relevant ruxolitinib + azacitidine clinical study report.
If you tell me the indication (and ideally the trial/NCT number or the paper you’re looking at), I can answer with the reported median duration of response/remission and the durability range.
Sources: None cited.